Carestream Earns Noteworthy Award for Best Customer Satisfaction in General X-ray

Survey Respondents Cite Carestream Quality and Technology Leadership

Carestream Health has earned IMV’s ServiceTrak™ award for Best Customer Satisfaction in General X-ray. The award represents Carestream’s high scores from customers in the areas of technology leadership, software ease of use, and system uptime and reliability.

“We’re honored to have this validation that we are satisfying the needs and expectations of our customers,” said Kendall Ryerson, Vice President, North America Sales at Carestream. “The survey responses support the feedback we repeatedly receive from our customers: that Carestream develops innovative solutions that deliver quantitative improvements in medical imaging; and our solutions are easy to use and reliable, helping to lower the costs of healthcare.”

The research findings also reveal that Carestream is the “most recommended” supplier in general X-ray; is ranked #1 in customer loyalty and training programs; and is a leader in system uptime. In addition, Carestream’s Net Promoter Scores (NPS) increased since 2021. This important metric is correlated to customer repurchase intentions and is known to have a causative effect on revenue and market share gains.

IMV produces the proprietary ServiceTrak reports based on extensive online surveys or phone interviews with radiology professionals in U.S. hospitals and non-hospital locations from IMV’s master database of general radiology X-ray system locations.

“This positive feedback from our customers should give imaging providers added confidence that they can rely on Carestream to deliver solutions that continually evolve to improve the imaging experience for staff and patients; and that enhance the interpretability of images for added diagnostic confidence to help improve clinical outcomes,” said Ms. Ryerson.

IMV, part of Science and Medicine Group, the leading market research and business intelligence provider to the laboratory diagnostic industry, recently published the category winners of the 2022 IMV ServiceTrak Imaging Awards.

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”
Exit mobile version